AGEN250117P1500
- 1.10
- 0.000.00%
Agenus Newsroom
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating
HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Cautious Hold Rating on Agenus Amid Strategic Realignment and Financial Challenges
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Express News | Agenus Inc: To Sharpen Its Focus on Botensilimab/Balstilimab (BOT/Bal) in Mss Colorectal Cancer
Express News | Agenus Inc - Plan Includes 60% Reduction in Annual External Expenditures
Express News | Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating
Promising Developments and Strategic Financing Enhance Agenus's Buy Rating Amidst Stock Volatility
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Agenus Inc. Reports Progress in Immunotherapy Development
Agenus | 10-Q: Q3 2024 Earnings Report
Agenus Is Maintained at Neutral by HC Wainwright & Co.
Agenus Analyst Ratings